Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series.

ISRN Oncol · 2014 · PMC4079952 · PMID 25006504

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

approaching significanceP = 0.053so close (0.05 < p ≤ 0.1)

Similarly, second or later line of treatment was not associated with decreased OS, although approaching significance ( P = 0.053).

also in 2,640 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.